CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Benzodiazepine and Z-Drug Use in Switzerland: Prevalence, Prescription Patterns and Association with Adverse Healthcare Outcomes

Open access
Landolt, Salome, Rosemann, Thomas, Blozik, Eva, Brüngger, Beat, Huber, Carola A · 2021 · Neuropsychiatric Disease and Treatment

Abstract

PURPOSE: This study aimed to give a nationwide comprehensive picture of the prevalence and prescription patterns of benzodiazepines (BZ) and Z-drugs (ZD) in Switzerland and to analyze the association with adverse health care outcomes. PATIENTS AND METHODS: A population-based, cross-sectional study was conducted, using a large health insurance database in Switzerland. Records from all adult patients with ≥1 prescription for a benzodiazepine and/or a Z-drug in 2018 were included. We calculated the prevalence of BZ and ZD user (extrapolated to the Swiss general population), the number of prescriptions and the type of provider (among each BZ and ZD only user). Multivariate logistic regression models were performed to estimate the association between drug prescription and the risk of hospitalization in different healthcare settings. RESULTS: Of a total of 844'692 patients, 95'179 had ≥1 BZ and/or ZD prescription in 2018. The extrapolated one-year prevalence for the general Swiss population was 8.1% for a BZ prescription, 3.5% for a ZD prescription, and 10.5% for a BZ and/or ZD prescription, and continuously increased with age. The majority of the elderly (over 65 years) had ≥1 prescription (BZ: 51.9%; ZD: 56.9%; BZ and/or ZD: 53.5). The proportion of patients with ≥6 prescriptions per year was 23.1% for BZ only user and 35.2% for ZD only user. Most patients had ≥1 prescription from a general practitioner. Regression models showed a higher likelihood to be admitted to acute care, psychiatry, rehabilitation, or nursing home with ≥1 prescription for a benzodiazepine and/or a Z-drug. CONCLUSION: This study is the first to give a nationwide overview of the current use of benzodiazepines and Z-drugs in Switzerland based on health insurance claims data. The results revealed a remarkably high prevalence among the general Swiss population, especially in older generations. The negative consequences of heavy BZ and ZD use are a crucial public health problem, that should be addressed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s290104

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Extrapolated prevalence of benzodiazepine use in the Swiss adult population by sex and age in 2018.
Figure 1 Extrapolated prevalence of benzodiazepine use in the Swiss adult population by sex and age in 2018.CC BY-NC · PubMed Central
Figure 2 Extrapolated prevalence of Z-drug use in the Swiss adult population by sex and age in 2018.
Figure 2 Extrapolated prevalence of Z-drug use in the Swiss adult population by sex and age in 2018.CC BY-NC · PubMed Central
Figure 3 Extrapolated prevalence of benzodiazepine and/or Z-drug use in the Swiss adult population by sex and age in 2018.
Figure 3 Extrapolated prevalence of benzodiazepine and/or Z-drug use in the Swiss adult population by sex and age in 2018.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Research works printed but not linked: 4

  1. 2017, Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
  2. Donato, 2005, Ital J Public Health, 2
  3. Holt, 2010, Dtsch Arztebl, 107, 543
  4. Cascade, 2008, Psychiatry, 5, 21

Cited by

See all 36

Metadata

Authors
Landolt, S., Rosemann, T., Blozik, E., Brüngger, B., & Huber, C. A.
Affiliations
  • University of Zurich (CH)
  • Helsana Group (Switzerland) (CH)
Corresponding author
Huber, Carola A
Venue
Neuropsychiatric Disease and Treatment
Published
2021-04
Volume
Volume 17
Pages
1021-1034
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
OpenAlex
W3154783048
Cited by
34
References
58
Citations by year
2026: 5 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 1
FWCI
3.45
Type
journal article
Language
en
Open access
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
benzodiazepines, Z-drugs, prescribing patterns, prevalence, hospitalization, older adults, general practitioners, health insurance claims data, Switzerland

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Benzodiazepine and Z-Drug Use in Switzerland: Prevalence, Prescription Patterns and Association with Adverse Healthcare Outcomes. https://app.cochat.ai/papers/10.2147/ndt.s290104
The paper
Landolt, S., Rosemann, T., Blozik, E., Brüngger, B., & Huber, C. A. (2021). Benzodiazepine and Z-Drug Use in Switzerland: Prevalence, Prescription Patterns and Association with Adverse Healthcare Outcomes. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/ndt.s290104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.